Targeting mutant p53 for cancer therapy: direct and indirect strategies

Targeting mutant p53 for cancer therapy: direct and indirect strategies

Abstract TP53 is a critical tumor-suppressor gene that is mutated in more than half of all human cancers. Mutations in TP53 not only impair its antitumor activity, but also confer mutant p53 protein oncogenic properties. The p53-targeted therapy approach began with the identification of compounds ca...

Full description

Bibliographic Details
Main Authors: Jiahao Hu, Jiasheng Cao, Win Topatana, Sarun Juengpanich, Shijie Li, Bin Zhang, Jiliang Shen, Liuxin Cai, Xiujun Cai, Mingyu Chen
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Journal of Hematology & Oncology
Subjects:
p53
Cancer therapy
MDM2 inhibitor
p53 restoration
Synthetic lethality
Noncoding RNA
Online Access:https://doi.org/10.1186/s13045-021-01169-0

Internet

https://doi.org/10.1186/s13045-021-01169-0

Similar Items